Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer Inc

2 Nov 2015 15:30

RNS Number : 2637E
Franklin Resources, Inc
02 November 2015
 



FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1967,

TAKEOVER RULES, 2007 (AS AMENDED)

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES

REPRESENTING 1% OR MORE

 

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

Franklin Resources, Inc.

Company dealt in

Pfizer Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

30 October 2015

 

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

69,408,694 1.12%

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

3,000 0.00%

Total

 

69,408,694 1.12%

 

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of relevant securities

Price per unit (Note 5)

Sale

18,233

33.8696 USD

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (Note 5)

 

 

 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction (Note 8)

 

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None stated.

 

Is a Supplemental Form 8 attached? (Note 9) YES

 

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

 

Product name,

e.g. call option

Written,

or purchased

Number of relevant securities to which the option or derivative relates

Exercise price

(Note 2)

Type, e.g. American, European etc.

Expiry date

Call Option

Written

3,000

36.00 USD

American

20 Nov 2015

 

 

 

 

Date of disclosure

2 November 2015

Contact name

Sally Culver

Telephone number

+1 (954) 847-2221

subsshholder@franklintempleton.com

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEUUUVRVSAARAA
Date   Source Headline
6th Nov 20153:27 pmRNSForm 8.3 - Pfizer Inc
6th Nov 20153:25 pmRNSForm 8.3 - Pfizer Inc Amendment
6th Nov 20153:22 pmRNSForm 8.3 - Pfizer Inc
6th Nov 20153:19 pmRNSForm 8.3 - Allergan plc
6th Nov 20153:18 pmRNSForm 8.3 - Pfizer, Inc.
6th Nov 20153:15 pmBUSForm 8.3 - Pfizer Inc.
6th Nov 20153:04 pmRNSForm 8.3 - [PFIZER INC]
6th Nov 20152:52 pmRNSForm 8.3 - Pfizer Inc
6th Nov 20152:45 pmRNSForm 8.3 - Allergan Plc
6th Nov 20152:34 pmRNSForm 8.3 - ALLERGAN PLC
6th Nov 20152:03 pmRNSForm 8.3 - Pfizer Inc.
6th Nov 201512:57 pmRNSForm 38.5(b) - Pfizer Inc.
6th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc
6th Nov 201511:40 amRNSForm 38.5(a) - Pfizer Inc
6th Nov 201511:30 amRNSRule 38.5 - Pfizer INC
6th Nov 201511:15 amRNSForm 8.1 - [Pfizer]
6th Nov 201511:12 amRNSForm 38.5a
6th Nov 201511:12 amRNSForm 38.5b
6th Nov 201511:10 amRNSForm 38.5b
5th Nov 20154:32 pmRNSForm 8.3 - Pfizer, Inc.
5th Nov 20154:19 pmRNSRule 38.5 - Replacement Pfizer INC
5th Nov 20154:18 pmRNSForm 8.3 - Pfizer Inc
5th Nov 20154:16 pmRNSRule 38.5 - Replacement Pfizer INC
5th Nov 20154:15 pmRNSRule 38.5 - Replacement Pfizer INC
5th Nov 20153:35 pmRNSForm 8.3 - Pfizer Inc. - Amendment
5th Nov 20153:35 pmRNSForm 8.3 - Pfizer Inc.
5th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
5th Nov 20153:30 pmRNSForm 8.3 - Allergan plc
5th Nov 20153:21 pmRNSForm 8.3 - [PFIZER INC]
5th Nov 20152:59 pmRNSForm 8.3 - Pfizer Inc
5th Nov 20152:53 pmBUSForm 8.3 - Pfizer Inc.
5th Nov 20152:43 pmRNSForm 8.3 - Allergan Plc
5th Nov 20152:14 pmRNSForm 8.3 - PFIZER INC
5th Nov 20152:12 pmRNSForm 8.3 - ALLERGAN PLC
5th Nov 201511:58 amRNSForm 38.5(b) - Pfizer Inc.
5th Nov 201511:49 amRNSForm 38.5b
5th Nov 201511:48 amRNSForm 38.5b
5th Nov 201511:47 amRNSForm 38.5b
5th Nov 201511:45 amRNSForm 38.5a
5th Nov 201511:45 amRNSForm 38.5a
5th Nov 201511:44 amRNSForm 8.1 - [Pfizer]
5th Nov 201511:39 amRNSForm 38.5(a) - Pfizer Inc.
5th Nov 201511:38 amRNSForm 38.5b
5th Nov 201511:26 amRNSRule 38.5 - Pfizer INC
5th Nov 201511:03 amRNSRule 38.5 - Pfizer INC
5th Nov 201511:01 amRNSRule 38.5 - Pfizer INC
4th Nov 20155:48 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:45 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:43 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:38 pmRNSRule 38.5 - Replacement Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.